NIH’s Public Access Policy:
Information and Tools to Ensure Compliance

Friday, March 29, 2013, 2:00-3:00 p.m.
Simons Auditorium, Simons Labs
2093 Constant Ave., KU west campus, Lawrence


Click here to view a recording of this seminar in Adobe Connect format.

Click here to view/download the PowerPoint for this seminar in pdf format.


For anyone with NIH funding, compliance with the NIH guidelines on public access to publications is critical, especially since the guidelines include plans for NIH to withhold funding for grants which produce publications that do not comply.   You are cordially invited to a seminar hosted by the KU-Lawrence COBREs, and presented by Alicia Reed, Grant Officer, Research and Graduate Studies/KU Center for Research.

  • Abstract:  This seminar will provide information for investigators on the NIH Public Access Policy and how they can ensure compliance with the policy.  Key information will include an overview of the policy, the main steps to compliance, and details on the tools that are available to assist with compliance including Pub Med Central and the National Center for Biotechnology Information bibliographic portal (My NCBI). The presentation will also include details about how to best utilize My MCBI, including its interface with eRA Commons for reporting and how to use the delegate functionality.

Recent News

February 2017
CMADP Project Investigators co-author Top Downloaded article in Lab on a Chip

CMADP Co-I awarded R01 from NIH National Cancer Institute

CMADP Graduate's research featured on cover of Genetics and in other journals

October 2016
CMADP Co-I receives Mathers Foundation grant

View all news »

Upcoming Events
Special seminar by Dr. Kevin W. Plaxco
Professor of Chemistry & Biochemistry
UC Santa Barbara

Wednesday, April 19, 2017 at 4:00pm
School of Pharmacy, Room 3020

"Counting molecules, dodging blood cells: real-time molecular measurements directly in the living body"
The development of technology capable of continuously tracking the levels of drugs, metabolites, and biomarkers in situ in the body would revolutionize our understanding of health and our ability to detect and treat disease. It would, for example, provide clinicians with a real-time window into organ function and would enable therapies guided by patient-specific, real-time pharmacokinetics, opening a new dimension in personalized medicine. In response my group has pioneered the development of a “biology-inspired” electrochemical approach to monitoring specific molecules that supports real-time measurements of arbitrary molecular targets (irrespective of their chemical reactivity) directly in awake, fully ambulatory subjects.
KU Today